Boston Scientific Corp
NYSE:BSX
Gross Margin
Boston Scientific Corp
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
138.9B USD |
68%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
221.6B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
177.8B USD |
67%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
134.3B USD |
64%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.3B USD |
66%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.3B USD |
45%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
49.8B EUR |
38%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
41.2B USD |
79%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
260.3B CNY |
64%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
32.6B USD |
61%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
31.3B USD |
58%
|
Boston Scientific Corp
Glance View
In the world of medical devices, Boston Scientific Corp. has carved out a significant niche, navigating the intersection of innovation and healthcare with precision. Founded in 1979, the company has built a robust reputation for developing a diverse range of products that address complex medical conditions. Boston Scientific operates through various segments, primarily focusing on interventional medical specialties that target areas such as cardiology, endoscopy, and neuromodulation. Through its relentless pursuit of innovation, the company continues to push boundaries, enhancing the diagnostic and therapeutic capabilities of physicians worldwide. The heartbeat of its operations lies in its extensive research and development endeavors, where cutting-edge technology meets advanced medical knowledge to produce life-enhancing solutions. At its core, Boston Scientific makes money by designing, manufacturing, and selling medical devices used in minimally invasive procedures. Its product portfolio includes solutions for coronary artery disease, heart rhythm disorders, peripheral artery disease, and many other critical ailments. By partnering with healthcare providers, Boston Scientific enables hospitals and clinics to offer high-quality, efficient care that caters to patient needs in a cost-effective manner. Revenue streams flow through direct sales channels and strategic partnerships across global markets, reflecting a combination of organic growth and strategic acquisitions. Moreover, the company actively reinvests in future technologies, ensuring its position as a pioneer in medical advancements while meeting the ever-evolving demands of the industry.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Boston Scientific Corp's most recent financial statements, the company has Gross Margin of 68.4%.
You don't have any saved screeners yet